We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 42.19 | 50.80 | 49.595 | 48.97 | 49.48 | 1,113,911 | 05:00:11 |
From May 2019 to May 2024
By Dominic Chopping
Denmark's Novo Nordisk A/S (NOVO-B.KO) said Monday it won't come back with a revised bid for Ablynx NV (ABLX) after the Belgian biopharmaceutical company agreed a takeover deal from Sanofi SA (SAN.FR).
Novo Nordisk had been courting Ablynx for the last couple of months, but said recently that the Ablynx board had rejected two of its bids and declined to engage in any discussions.
Novo Nordisk's latest offer, made Dec. 22, 2017, was a 2.6 billion-euro ($3.2 billion) bid consisting of EUR28.00 upfront and EUR2.50 in Contingent Value Rights.
Ablynx accepted a EUR3.9 billion offer from Sanofi on Monday, saying the French drug maker's bid "represents compelling value for shareholders and maximizes the potential of our pipeline."
In response, Novo Nordisk confirmed it would not be making a revised proposal.
Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @domchopping @WSJNordics
(END) Dow Jones Newswires
January 29, 2018 05:44 ET (10:44 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
